Methylation mediated silencing of TMS1/ASC gene in prostate cancer
Open Access
- 18 July 2006
- journal article
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 5 (1), 1-10
- https://doi.org/10.1186/1476-4598-5-28
Abstract
Background: Transcriptional silencing associated with aberrant promoter methylation has been established as an alternate pathway for the development of cancer by inactivating tumor suppressor genes. TMS1 (Target of Methylation induced Silencing), also known as ASC (Apoptosis Speck like protein containing a CARD) is a tumor suppressor gene which encodes for a CARD (caspase recruitment domain) containing regulatory protein and has been shown to promote apoptosis directly and by activation of downstream caspases. This study describes the methylation induced silencing of TMS1/ASC gene in prostate cancer cell lines. We also examined the prevalence of TMS1/ASC gene methylation in prostate cancer tissue samples in an effort to correlate race and clinico-pathological features with TMS1/ASC gene methylation. Results: Loss of TMS1/ASC gene expression associated with complete methylation of the promoter region was observed in LNCaP cells. Gene expression was restored by a demethylating agent, 5-aza-2'deoxycytidine, but not by a histone deacetylase inhibitor, Trichostatin A. Chromatin Immunoprecipitation (ChIP) assay showed enrichment of MBD3 (methyl binding domain protein 3) to a higher degree than commonly associated MBDs and MeCP2. We evaluated the methylation pattern in 66 prostate cancer and 34 benign prostatic hyperplasia tissue samples. TMS1/ASC gene methylation was more prevalent in prostate cancer cases than controls in White patients (OR 7.6, p 0.002) while no difference between the cases and controls was seen in Black patients (OR 1.1, p 0.91). Conclusion: Our study demonstrates that methylation-mediated silencing of TMS1/ASC is a frequent event in prostate cancer, thus identifying a new potential diagnostic and prognostic marker for the treatment of the disease. Racial differences in TMS1/ASC methylation patterns implicate the probable role of molecular markers in determining in susceptibility to prostate cancer in different ethnic groups.Keywords
This publication has 37 references indexed in Scilit:
- Ethnic group‐related differences in CpG hypermethylation of the GSTP1 gene promoter among African‐American, Caucasian and Asian patients with prostate cancerInternational Journal of Cancer, 2005
- Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer PatientsClinical Cancer Research, 2004
- Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemiaBlood, 2004
- Aberrant Methylation and Down-Regulation of TMS1/ASC in Human GlioblastomaThe American Journal of Pathology, 2004
- ASC/TMS1, a caspase‐1 activating adaptor, is downregulated by aberrant metylation in human melanomaInternational Journal of Cancer, 2003
- Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancerInternational Journal of Cancer, 2003
- Hypermethylation of GSTP1, CD44, and E‐cadherin genes in prostate cancer among US Blacks and WhitesThe Prostate, 2003
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003
- Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF‐κB and caspase‐1FEBS Letters, 2002
- Methylation-mediated Silencing of TMS1/ASC Is Accompanied by Histone Hypoacetylation and CpG Island-localized Changes in Chromatin ArchitectureJournal of Biological Chemistry, 2002